
Fiasp Penfill 100 Iu/ml 3 ML Cartridge
Salt Composition: Insulin Aspart (100IU/ml)
Expiry Date: 01/2028
Inclusive of all taxes
5 Cartridge
About The Product
Very fast-acting insulin, used at or before meals.
Description
Fiasp Penfill 100 Iu/ml 3 ML Cartridge is mainly used to give insulin for diabetes patient. Fiasp Penfill 100 IU/ml 3 ml Cartridge is a fast-acting insulin aspart solution.
When combined with long-acting insulin, it offers quick blood sugar control when administered before to or soon after meals. Fiasp Penfill 100 Iu/ml 3 ML Cartridge contains Insulin aspart that increases glucose absorption.
Uses
- Gives Insulin
Side Effects
Fiasp Penfill 100 Iu/ml 3 ML Cartridge cause multiple side effects that ranges from common to serious.
- Hypoglycemia
- Injection site reactions
- Weight gain
- Nausea
- Diarrhea
- Upper respiratory infections
- Severe Hypoglycemia
- Hypokalemia
- Allergic reactions
- Pump failure
How To Use
- Fiasp Penfill 100 Iu/ml 3 ML Cartridge should be administered subcutaneously using a compatible reusable pen like NovoPen by a doctor or an experienced nurse.
- Do not Self Administer.it offers quick blood sugar control when administered before to or soon after meals.
How It Works
- Fiasp Penfill 100 Iu/ml 3 ML Cartridge contains Insulin aspart that inhibits hepatic glucose production and increases glucose absorption via GLUT4 transporters via binding to insulin receptors on muscle and fat cells.
- Additionally, it increases protein synthesis and lipogenesis while inhibiting lipolysis and proteolysis.
Safety Advice
FAQs
Fiasp Penfill 100 Iu/ml 3 ML Cartridge is mainly used to give insulin for diabetes patient.
References
- Gammeltoft, S., Hansen, B. F., Dideriksen, L., Lindholm, A., Schäffer, L., Trüb, T., ... & Kurtzhals, P. (1999). Insulin aspart: a novel rapid-acting human insulin analogue. Expert Opinion on Investigational Drugs, 8(9), 1431-1442. https://pubmed.ncbi.nlm.nih.gov/15992160/
- Lindholm, A., & Jacobsen, L. V. (2001). Clinical pharmacokinetics and pharmacodynamics of insulin aspart. Clinical pharmacokinetics, 40(9), 641-659. https://pubmed.ncbi.nlm.nih.gov/11605714/
- Owens, D., & Vora, J. (2006). Insulin aspart: a review. Expert opinion on drug metabolism & toxicology, 2(5), 793-804. https://pubmed.ncbi.nlm.nih.gov/17014395/
- Hermansen, K., Bohl, M., & Schioldan, A. G. (2016). Insulin aspart in the management of diabetes mellitus: 15 years of clinical experience. Drugs, 76(1), 41-74.
Medical Disclaimer
Accurate, reviewed information to support informed healthcare decisions
Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.
The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.
This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.
Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.
